Valuable insights from the epacadostat plus pembrolizumab clinical trials in solid cancers

Ítems similars

• Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
  per: Andrea Necchi, et al.
  Publicat: (2024-07-01)
• Valuable insights from the epacadostat plus pembrolizumab clinical trials in solid cancers
  per: Tara C. Mitchell
  Publicat: (2024-07-01)
• The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
  per: Eleonora Panfili, et al.
  Publicat: (2023-04-01)
• Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells
  per: Sofia Rossini, et al.
  Publicat: (2024-01-01)
• Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
  per: Takaaki Tokito, et al.
  Publicat: (2024-07-01)